Flex Pharma to Report First Quarter 2018 Financial Results on May 2, 2018
BOSTON--(BUSINESS WIRE)--Apr. 25, 2018--
Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company
that is developing innovative and proprietary treatments for cramps and
spasticity associated with severe neurological diseases such as multiple
sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral
sclerosis (ALS) under FDA Fast Track designation, announced today that
it will report its financial results for the first quarter ended March
31, 2018 on Wednesday, May 2, 2018 before the U.S. financial markets
open. The Company will host a conference call and webcast at 9:00 a.m.
ET to discuss first quarter 2018 financial results and provide a
business update. Individuals interested in participating in the call
should dial (855) 780-7202 (U.S. and Canada) or (631) 485-4874
A live webcast may be accessed in the Investors & Media section of the
Company's website at www.flex-pharma.com.
Please log on to the Flex Pharma website approximately 15 minutes prior
to the scheduled webcast to ensure adequate time for any software
downloads that may be required. A replay of the webcast will be
available on Flex Pharma's website for 90 days following the event.
About Flex Pharma
Flex Pharma, Inc. is a clinical-stage biotechnology company that is
developing innovative and proprietary treatments in Phase 2 randomized,
controlled trials for cramps and spasticity associated with the severe
neurological diseases of ALS, MS and peripheral neuropathies such as
Charcot-Marie-Tooth (CMT). The Company’s lead candidate, FLX-787, is
being developed under Fast Track designation for the treatment of severe
muscle cramps associated with ALS. Flex Pharma was founded by National
Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate),
and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels
and neurobiology, along with Christoph Westphal, M.D., Ph.D.
to Tweet this News
View source version on businesswire.com: https://www.businesswire.com/news/home/20180425006590/en/
Source: Flex Pharma, Inc.
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
Relations & Corporate Communications